Welcome to our dedicated page for Metagenomi Therapeutics news (Ticker: MGX), a resource for investors and traders seeking the latest updates and insights on Metagenomi Therapeutics stock.
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is a biotechnology company focused on in vivo genome editing and precision genetic medicines. Its news flow centers on progress across its proprietary gene editing toolbox and its therapeutic pipeline, particularly the MGX-001 program for hemophilia A and additional programs in secreted protein deficiencies and cardiometabolic diseases.
News updates for MGX often highlight preclinical data releases, such as non-human primate studies demonstrating durable and therapeutically relevant factor VIII (FVIII) activity for MGX-001, dose range finding results, and safety observations that inform proposed clinical dosing strategies. The company also issues press releases on pipeline prioritization, describing decisions to focus resources on later-stage preclinical assets and its most advanced gene-editing capabilities.
Investors and observers can expect coverage of collaboration milestones, including developments in Metagenomi’s partnership with Ionis Pharmaceuticals on cardiometabolic targets like APOC3. Scientific and medical conference participation is another recurring theme, with the company presenting data at meetings such as the American Society of Gene & Cell Therapy (ASGCT), TIDES USA, and other conferences where it shares advances in compact nucleases, CRISPR-associated transposases (CAST), and AI-guided metagenomic discovery.
MGX news also includes corporate and financial updates, such as quarterly financial results, cash runway commentary, organizational changes, board appointments, and the corporate name change to Metagenomi Therapeutics, Inc. For those following MGX, this news page provides a consolidated view of scientific progress, collaboration updates, and corporate developments reported in press releases and related communications.
Metagenomi (Nasdaq: MGX) announced that its abstract on Factor VIII gene insertion has been accepted for oral presentation at the American Society of Hematology (ASH) 66th Annual Meeting in December 2024. The presentation will showcase preclinical proof-of-concept data for their lead candidate MGX-001, which aims to provide a single, curative treatment for hemophilia A.
The research demonstrates durable Factor VIII expression in nonhuman primates, addressing current therapy limitations that fail to prevent breakthrough bleeding. The presentation, led by VP Preclinical Alan Brooks, PhD, is scheduled for December 9, 2024, at 5:30 PM in San Diego Convention Center.
Metagenomi presented groundbreaking results for its Adenine Base Editors (ABEs) at the European Society of Gene and Cell Therapy Annual Congress in Rome. The company's ABE platform demonstrated exceptional performance across key metrics: over 95% genome targetability, achieving 95% protein knockdown in primary T-cells through triplex editing, and highly specific on-target deamination with no detectable translocations.
The platform showed excellent tolerability with no adverse effects on cell viability or expansion. Notable advantages include compatibility with various non-viral methods of site-specific template integration, enabling an all-in-one editing solution for next-generation cell therapies. This positions Metagenomi's ABE technology as a promising tool for both in vivo genome editing programs and ex vivo cell therapy applications.
Metagenomi (Nasdaq: MGX) presented a poster at the AIChE 7th International Conference on CRISPR Technologies, highlighting their SMART adenine base editors (ABEs). These compact editors are small enough to be packaged into a single adeno-associated virus (AAV), potentially addressing a key challenge in in vivo gene editing.
The company's SMART platform demonstrates improved editing efficiency across multiple targets and cell types, enabling pursuit of neuromuscular targets. This approach could be advantageous for treating diseases like Duchenne muscular dystrophy, ALS, and Charcot-Marie-Tooth disease type 1A.
Metagenomi has optimized the SMART platform through structure-guided engineering and advanced artificial intelligence (AI) tools, showcasing the importance of leveraging multiple techniques to advance next-generation gene editing systems.
Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference on September 30, 2024. The company will be involved in two key events:
1. A fireside chat from 2:30 PM to 3:00 PM ET, featuring CEO and Founder Brian Thomas, CMO Dr. Sarah Noonberg, and SVP Preclinical Alan Brooks.
2. A panel discussion titled "Genome editing for gene insertion and gene correction - where we are and what's next" from 5:00 PM to 5:30 PM ET, with CEO Brian C. Thomas participating.
A live webcast of the fireside chat will be available on the company's investor relations website, with replays of both events accessible for a time.
Metagenomi (Nasdaq: MGX) has announced promising 12-month durability data for its lead hemophilia A program, MGX-001. The preclinical study in nonhuman primates (NHPs) demonstrated durable Factor VIII (FVIII) activity levels through twelve months, with two NHPs showing normal/near-normal levels (82% and 41%) and one in the mild hemophilia range (9%). The treatment, involving a single dose of AAV followed by an LNP containing Metagenomi's novel nuclease, was generally well-tolerated.
Key findings include:
- Consistent FVIII activity levels from 3-6 months to 9-12 months
- Gene integration in liver biopsies correlating with FVIII activity
- Program on track for IND filing in 2026
Metagenomi aims to provide a one-time, curative treatment for adults and children with hemophilia A and plans to leverage this platform for other secreted protein disorders.
Metagenomi (Nasdaq: MGX) presented advancements in its AI-enabled SMART Editing Platform at the CRISPR Frontiers Conference. The company showcased AI-generated compact SMART nucleases with robust genome editing activity in mammalian cells. These tools, fitting within size-constrained delivery technologies, may enable broader disease targeting.
Key highlights include:
- AI-based gene editing variants showing high efficiency in mammalian cells
- Compact base editors less than 1,000 amino acids long
- De novo, AI-generated synthetic nucleases demonstrating robust activity
- Rational engineering achieving saturating levels of editing in human cells
Metagenomi's approach combines its metagenomics database of over 11 billion proteins with AI to create novel gene editing tools, potentially accelerating drug development and opening new therapeutic applications.
Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in two upcoming investor conferences. The company will present at the Wells Fargo Healthcare Conference on September 4, 2024, and the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024.
Key executives, including CEO Brian Thomas, CMO Dr. Sarah Noonberg, SVP Preclinical Alan Brooks, and CFO Pamela Wapnick, will represent Metagenomi at these events. The presentations will be available via live webcast on the company's investor relations website, with replays accessible for a time.
Metagenomi specializes in developing curative therapeutics using its proprietary, metagenomics-derived toolbox. The company's comprehensive genome editing toolkit includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, positioning Metagenomi to address a wide range of genetic mutations.
Metagenomi (Nasdaq: MGX) reported Q2 2024 financial results and business updates. Key highlights include:
1. Declared MGX-001 as lead candidate for hemophilia A treatment
2. All Wave 1 Ionis collaboration programs advancing in lead optimization
3. Achieved milestone with Affini-T related to licensed technology
4. $299.9M in cash and equivalents; runway into 2027
5. R&D expenses increased to $28.3M from $22.7M YoY
6. G&A expenses rose to $8.6M from $6.6M YoY
The company plans to present 12-month NHP durability study data for MGX-001 in September 2024, accelerated from late 2024. Metagenomi aims to file an IND for hemophilia A in 2026 and nominate 1-2 development candidates for cardiometabolic programs in 2025.
Metagenomi (Nasdaq: MGX), a precision genetic medicines company, will present at the 2024 Jefferies Global Healthcare Conference on June 5, 2024. CEO Brian C. Thomas will deliver the presentation at 11:30 a.m. Eastern Time, and the company will also host one-on-one investor meetings during the conference from June 5-6. The presentation will be live-streamed on Metagenomi's website. A replay will be available for 30 days post-event.
Metagenomi specializes in developing curative therapeutics using a metagenomics-derived gene editing toolbox. Their technology harnesses microbial evolution over four billion years to create tools capable of correcting genetic mutations in the genome. The toolbox includes programmable nucleases, base editors, and RNA and DNA integration systems.
Metagenomi (MGX) announced its Q1 2024 financial results, revealing a cash position of $327.4 million, sufficient to support operations until 2027. The company's key scientific presentations showcased advancements in gene editing for Hemophilia A and other genetic conditions. At the World Federation of Hemophilia Congress, Metagenomi highlighted Factor VIII expression within the therapeutic range in non-human primates, with a development candidate expected by mid-2024. At the ASGCT meeting, they presented data demonstrating a five-fold increase in genome targetability using MGX base editing and successful large gene integration in human cells. Additionally, Metagenomi regained full rights to its gene editing technologies, previously held by ModernaTX. Financially, the company reported increased R&D expenses ($31.4M) and G&A expenses ($8.8M), leading to a net loss of $25.1 million, compared to $16.1 million in Q1 2023.